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ABSTRACT
Background The asthma-associated gene urokinase
plasminogen activator receptor (uPAR) may be involved
in epithelial repair and airway remodelling. These
processes are not adequately targeted by existing
asthma therapies. A fuller understanding of the
pathways involved in remodelling may lead to
development of new therapeutic opportunities. uPAR
expression in the lung epithelium of normal subjects and
patients with asthma was investigated and the
contribution of uPAR to epithelial wound repair in vitro
was studied using primary bronchial epithelial cells
(NHBECs).
Methods Bronchial biopsy sections from normal
subjects and patients with asthma were immunostained
for uPAR. NHBECs were used in a scratch wound model
to investigate the contribution of the plasminogen
pathway to repair. The pathway was targeted via
blocking of the interaction between urokinase
plasminogen activator (uPA) and uPAR and
overexpression of uPAR. The rate of wound closure and
activation of intracellular signalling pathways and matrix
metalloproteinases (MMPs) were measured.
Results uPAR expression was signiﬁcantly increased in
the bronchial epithelium of patients with asthma
compared with controls. uPAR expression was increased
during wound repair in monolayer and air-liquid interface-
differentiated NHBEC models. Blocking the uPAeuPAR
interaction led to attenuated wound repair via changes in
Erk1/2, Akt and p38MAPK signalling. Cells engineered to
have raised levels of uPAR showed attenuated repair via
sequestration of uPA by soluble uPAR.
Conclusions The uPAR pathway is required for efﬁcient
epithelial wound repair. Increased uPAR expression, as
seen in the bronchial epithelium of patients with asthma,
leads to attenuated wound repair which may contribute
to the development and progression of airway
remodelling in asthma. This pathway may therefore
represent a potential novel therapeutic target for the
treatment of asthma.
INTRODUCTION
We have previously identiﬁed urokinase plasmin-
ogen activator receptor (uPAR, PLAUR, CD87) as
an asthma-associated gene showing genetic associ-
ation between single nucleotide polymorphisms
(SNPs) spanning the uPAR gene (PLAUR) and
asthma susceptibility, bronchial hyper-responsive-
ness (BHR), decline in lung function and plasma/
serum levels of uPAR.
1 These data suggest that
variation at the PLAUR locus may predispose indi-
viduals with asthma to accelerated decline in lung
function, a marker of airway remodelling.
uPAR is the key receptor in the plasminogen
pathway which binds and activates the serine
protease urokinase plasminogen activator (uPA,
PLAU), leading to an extracellular protease cascade
implicated in mechanisms including cell migration,
matrix metalloproteinase (MMP) activation and
cytokine release.
2 uPAR also coordinates extracel-
lular signals and transfers them to intracellular
signalling responses via co-receptors including
integrins, leading to changes in processes including
proliferation, migration and adhesion.
2e4 Soluble
and cleaved forms of uPAR shed from the cell
surface participate in distinct signalling pathways
as well as acting as a decoy receptor preventing uPA
binding to surface uPAR.
5e7 Plasminogen activator
inhibitor 1 (PAI-1, SERPINE1) binds to uPA and
prevents its activation.
89PAI-1 also binds to
vitronectin, blocking aVb3 integrin and uPAR
binding, inhibiting cell adhesion and altering
migration.
10 11
A key feature of asthma (especially severe
asthma) is airway remodelling.
12 There is growing
support for a role of dysregulated or aberrant
epithelial repair in this process,
13 14 indicating
a need to further understand the mechanisms of
bronchial epithelial repair. Many of the processes in
which the plasminogen pathway is involved are
features of epithelial repair and airway remodelling.
An in vivo human study investigating bronchial
epithelial repair found increased uPA and PAI-1
transcripts in brushings taken 7 days after injury,
suggesting that this pathway is involved
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Asthmaspeciﬁcally in epithelial repair processes in the bronchi.
15
Another study using a mouse asthma model showed that
inhalation of uPA could protect against subepithelial ﬁbrosis and
airway hyper-responsiveness,
16 indicating that the plasminogen
pathway plays a role in airway remodelling.
We hypothesised that genetically predisposed dysregulated
expression of uPAR may be a feature of asthma and that uPAR
plays a critical role in epithelial repair. We aimed to investigate
uPAR expression in normal and asthmatic lung to determine
whether uPAR is increased in the epithelium of subjects with
asthma. A scratch wound model in primary human bronchial
epithelial cells (NHBEC) was used to investigate the role of
uPAR and the plasminogen pathway in epithelial wound repair.
Our data support the hypothesis that uPAR is increased in the
bronchial epithelium in subjects with asthma, that the interac-
tion between uPA and uPAR is critical for efﬁcient bronchial
epithelial wound repair in vitro and that increased expression of
uPAR, as observed in asthma, attenuates in vitro repair.
METHODS
Immunostaining of bronchial biopsies
Sections taken from control and asthmatic glycomethacrylate-
embedded bronchial biopsies were stained using anti-uPAR
(sc-32764, Santa Cruz Biotechnology, Heidelberg, Germany) or
an appropriate isotype control. A semi-quantitative score of
staining was used to deﬁne expression in the epithelium
(0¼none, 1¼low, 2¼moderate, 3¼high; mean of two sections
per donor, scored by a blinded observer, ﬁgure 1). Patient details
and clinical characterisation are shown in the online
supplement.
Cell culture
NHBEC (Lonza, Wokingham, UK) were used at passage 3e4i n
growth factor-supplemented medium (BEGM, Lonza) for
monolayer experiments. Cells were differentiated at passage 3 at
the aireliquid interface (ALI) according to a previously published
method (see online supplement).
17 18 Three donors were used in
this study (see table E1 in online supplement). Details of wound
repair experiments, preparation and transfection of plasmids for
overexpression of uPAR are shown in the online supplement.
Immunoﬂuorescence of cultured cells
Monolayer NHBECs were grown on glass chamber slides for
immunoﬂuorescence, ALI cultured cells were ﬁxed in situ on
inserts and transferred to glass slides for visualisation. The cells
were ﬁxed using 4% formaldehyde and permeabilised with
0.15% Triton-X before blocking with 10% goat serum. They
were incubated with primary antibodies at 48C overnight and
Figure 1 Urokinase plasminogen
activator receptor (uPAR) is increased
in asthmatic bronchial epithelium.
Bronchial biopsy sections from controls
and subjects with asthma were stained
with (A) isotype control or (BeE) anti-
uPAR antibody. A semiquantitative
staining score of 0¼none (B), 1¼low
(C), 2¼moderate (D) or 3¼high (E) was
applied to each section and two
sections were scored per subject. (F)
uPAR protein levels were higher in the
bronchial epithelium of patients with
asthma than in normal controls,
irrespective of severity (p¼0.002).
*p<0.05, **p<0.01. GINA, Global
Initiative for Asthma.
478 Thorax 2012;67:477e487. doi:10.1136/thoraxjnl-2011-200508
AsthmaAlexa488-labelled secondary antibodies for 1 h at room temper-
ature (table E2 in online supplement). The cells were visualised
using the Zeiss spinning disc confocal microscope and Volocity
software (Perkin Elmer, Cambridge, UK).
Quantitative PCR
Cultured cells were lysed and RNA was extracted using silica
columns (RNeasy mini kit, Qiagen, Crawley, UK). cDNA was
synthesised using Superscript II (Invitrogen, Paisley, UK) and
random hexamer primers according to the manufacturer’s
instructions. mRNA levels of uPAR, uPA and PAI-1 were quan-
tiﬁed using a series of quantitative PCR assays (see table E3 in
online supplement). Quantitative PCR was performed using
TaqMan gene expression master mix (Applied Biosystems,
Warrington, UK) and HPRT1 endogenous control
(Hs01003267_m1, Applied Biosystems) on a Stratagene
MxPro3005 machine using 40 cycles of 958C for 15 s and 608C
for 60 s. Data were normalised using the housekeeper (HPRT1)
and the 2
 DCt method.
Western blotting
Cells were lysed in 13 SDS loading buffer. Equal volumes of
lysates were separated by 10% SDS-PAGE under reducing
conditions. Proteins were transferred to a PVDF membrane and
probed using a panel of primary antibodies (see table E4 in online
supplement) and HRP-conjugated secondary antibodies. Binding
was visualised by enhanced chemiluminescence (ECL, Amer-
sham Biosciences, Little Chalfont, UK). Membranes were
stripped using Restore Western blot stripping buffer (Thermo
Fisher Scientiﬁc, Cramlington, UK) and re-probed for loading
controls. Densitometry of protein bands used ImageJ 1.41 (NIH,
USA http://rsbweb.nih.gov/ij/). For statistical analysis, data
were normalised to b-actin and exposure levels.
Analysis of supernatant proteins
DuoSet enzyme-linked immunosorbent assays (ELISA) (R&D
Systems, Abingdon, UK) were used to quantify soluble uPAR
(suPAR), uPA and PAI-1 in cell culture supernatants following
the manufacturer’s recommendations. Semi-quantitative
measurement of MMP-2 and MMP-9 activity was obtained using
gelatin zymography (see online supplement). MMP-9 activity
was further quantiﬁed using the FluorokineE assay (R&D
Systems). Plasmin activity in supernatants from ALI cultures
was measured using the SensoLyte AFC Plasmin Activity Kit
(AnaSpec, Cambridge Bioscience, Cambridge, UK). Plasmin
activity in supernatants from monolayer cultures was below the
detection limit of this assay.
Statistical analysis
GraphPad Prism 5.03 for Windows (GraphPad Software, San
Diego, California, USA) was used for statistical analysis. Semi-
quantitative data were analysed using the ManneWhitney or
KruskaleWallis tests while quantitative data were analysed
using the Student t test or ANOVA with Bonferonni post-test.
p<0.05 was considered signiﬁcant.
RESULTS
uPAR protein levels are increased in asthma bronchial
epithelium
Bronchial biopsies were taken from nine normal subjects and 27
individuals with asthma (see table E5 in online supplement).
Asthma cases showed a range of severities and were divided
into mild to moderate (Global Initiative for Asthma (GINA)
severity 1e3, n¼15) and severe asthmatics (GINA 4e5,
n¼12).
19 Analysis of epithelial immunostaining for uPAR used
a semi-quantitative score (ﬁgure 1BeE represents scores 0e3f o r
illustration). Biopsies taken from subjects with asthma showed
as i g n i ﬁcant increase in uPAR levels compared with control
subjects, particularly in the epithelial layer (p¼0.002); however,
there was no difference between subjects with mild to
moderate or severe asthma (ﬁgure 1F). Subjects with asthma
compared with controls showed decreased percentage predicted
forced expiratory volume in 1 s (FEV1)( n o ts i g n i ﬁcant) and
increased BHR to methacholine (p<0.0001). There was no
signiﬁcant difference between groups for age, gender, atopy,
smoking status or smoking pack-years, but there was a trend
towards increased smoking in subjects with asthma. The
analysis was repeated in non-smokers only and showed similar
results (data not shown).
Induction of uPAR is a feature of wound repair in primary
NHBECs in vitro
Conﬂuent monolayer NHBEC cultures were scratch wounded
and followed until closure over 24 h (n¼4; see ﬁgure E1A in
online supplement). Immunostaining 4 h after wounding
showed increased uPAR protein expression in cells at the wound
edge (ﬁgure 2A). Increased mRNA levels of uPAR (p<0.001 at
8h ,ﬁgure 2B) and PAI-1 (p<0.001 at 4 h, ﬁgure 2D) but not uPA
(ﬁgure 2C) were detected during the wound repair process.
Wounding increased levels of soluble uPAR (suPAR) in super-
natants after wounding (p<0.001 at 24 h, ﬁgure 2E). Analysis of
MMPs as a marker of plasminogen pathway activity in super-
natants taken at 24 h after wounding using two different
methods (zymography (ﬁgure 2H) and MMP-9 activity assay
(ﬁgure 2I)) showed that pro-MMP-2 was signiﬁcantly reduced
24 h after wounding (p¼0.03).
Blocking the uPAeuPAR interaction attenuates wound repair
in primary NHBECs in vitro
The uPAeuPAR interaction can be blocked using anti-uPA
antibody.
20e22 This blocking attenuated wound repair in
monolayer NHBECs in a dose-dependent manner (p<0.001 at
40 mg/ml, ﬁgure 3A, n¼4). Isotype control antibody caused
a small decrease in the area healed at 24 h only (p<0.01), while
an anti-uPAR domain II antibody anticipated not to affect the
uPAeuPAR interaction had no effect on wound repair. Anti-
uPA-treated cells showed a signiﬁcantly reduced area healed
compared with medium control, isotype control and non-
blocking antibody control (data not shown). Addition of
blocking antibody at the time of wounding led to lower levels of
suPAR (p¼0.04, ﬁgure 3B), uPA (p<0.001, ﬁgure 3C) and PAI-1
(p<0.001, ﬁgure 3D) in the supernatants 24 h after wounding.
Addition of blocking antibody did not affect MMP-2/MMP-9
expression or MMP-9 activity (ﬁgure 3E,F).
Blocking the uPAeuPAR interaction alters Erk/Akt/p38MAPK
signalling pathways
Signalling pathways implicated in wound repair are also
downstream of uPAR activation. To investigate these path-
ways, NHBECs were lysed 5 min after wounding. Cells were
also incubated with the anti-uPA blocking antibody at the time
of wounding. Western blotting was used to investigate the
expression and activation of Akt (ﬁgure 4A), Erk1/2 (ﬁgure 4B)
and p38MAPK (ﬁgure 4C) in these samples by measuring
phosphorylated and total proteins and the ratio of these forms
(representative of n¼8 control/untreated, n¼4b l o c k i n g ) .I n
control cells, phosphorylation of Erk1/2 (p<0.001, ﬁgure 4H,K)
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Asthmaand p38MAPK (p<0.001, ﬁgure 4I,L) but not Akt (ﬁgure 4G,J)
was increased on wounding, with no effect on total protein
(ﬁgure 4DeF). Addition of blocking antibody caused an
increase in total p38 (p¼0.004 unwounded, ﬁgure 4F). There
was also a decrease in phospho-Erk1/2 (p¼0.004 unwounded,
p¼0.004 wounded, ﬁgure 4H) and an increase in phospho-p38
(p¼0.0081 unwounded, p¼0.004 wounded, ﬁgure 4I) in both
unwounded and wounded cells. Phospho-p38 was not signiﬁ-
cantly increased on wounding when cells were treated with
blocking antibody (ﬁgure 4I,L), although there was increased
Figure 2 Induction of urokinase plasminogen activator receptor (uPAR) is a feature of primary bronchial epithelial cell (NHBEC) wound repair. Wound
repair in monolayer NHBECs occurs over 24 h (n¼4). (A) uPAR expression increases in cells at the wound edge 4 h after wounding (arrows). uPAR (B,
E), urokinase plasminogen activator (uPA) (C, F) and plasminogen activator inhibitor 1 (PAI-1) (D, G) mRNA and protein levels in supernatants
measured in wounded/unwounded cells over 24 h. Matrix metalloproteinase (MMP)-2 and MMP-9 activity measured at 24 h by zymography (H) and
ELISA-based MMP-9 activity assay (I). *p<0.05, ***p<0.001.
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Asthmaphosphorylation of Akt (ﬁgure 4G,J, p¼ns) and Erk1/2 (ﬁgure
4H,K, p<0.05).
Parallel experiments using a non-blocking isotype-matched
anti-uPAR domain II antibody showed no signiﬁcant effect on
signalling compared with untreated cells (data not shown).
Increased uPAR levels lead to receptor shedding and attenuated
wound repair
NHBECs were transiently transfected with control (pcDNA3)
or membrane uPAR overexpression (pc-uPAR) plasmids.
Increased uPAR was conﬁrmed by western blotting (ﬁgure 5A,
representative of n¼3), immunoﬂuorescence (ﬁgure 5B) and
quantitative PCR (p¼0.008, ﬁgure 5C). Supernatant suPAR was
also signiﬁcantly increased (p¼0.04, ﬁgure 5D). Levels of uPA
(p¼0.004, ﬁgure 5E) but not PAI-1 (ﬁgure 5F) in supernatants
were signiﬁcantly reduced 24 h after transfection, potentially
due to uPA sequestration by suPAR. At baseline (24 h after
transfection, prior to wounding), cells overexpressing uPAR
showed a trend towards decreased pro-MMP-2 and increased
pro-MMP-9 levels by zymography (ﬁgure 5G), which was
signiﬁcant in the MMP-9 activity assay (p¼0.005 active MMP-
9, p<0.001 total MMP-9, ﬁgure 5H). Increased uPAR expression
attenuated wound repair (p<0.001, n¼5, ﬁgure 5I). To deter-
mine whether this is due to intracellular signalling or soluble
factors, conditioned supernatant from control or uPAR over-
expressing cells was added to non-transfected cells. Adding back
conditioned supernatants at the time of wounding had no
signiﬁcant effect on the rate of repair (ﬁgure 5J); however, cells
pretreated with uPAR-conditioned supernatants for 24 h
showed a small but signiﬁcant attenuation of repair (p¼0.03,
ﬁgure 5K).
Increased uPAR does not affect Erk/Akt/p38MAPK signalling
after wounding
Signalling activation was investigated in cells transfected with
pcDNA3 or pc-uPAR. These cells were wounded 24 h after
transfection and harvested after a further 5 min (n¼3).
Measurement of Erk1/2, Akt and p38MAPK showed no signiﬁ-
cant differences in activation state between the two cell types in
unwounded or wounded cells (data not shown).
Figure 3 (A) Blocking the interaction
between urokinase plasminogen
activator (uPA) and urokinase
plasminogen activator receptor (uPAR)
attenuates the rate of wound repair
(n¼4). (B) Soluble uPAR (suPAR), (C)
uPA and (D) plasminogen activator
inhibitor 1 (PAI-1) levels decrease in
supernatants at 24 h in the presence of
blocking antibody. (E) Zymography and
(F) an ELISA-based assay detect matrix
metalloproteinase (MMP)-2 and MMP-9
activity at 24 h. *p<0.05, **p<0.01,
***p<0.001.
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AsthmauPAR induction is a feature of wound repair responses
in a differentiated NHBEC model
We analysed uPAR pathway components in an ALI differenti-
ated NHBEC model (representative of n¼2). NHBECs were
cultured at ALI for 21 days before wounding. This model
develops signiﬁcant transepithelial electrical resistance and
expression of markers of ciliated (b-tubulin IV, ﬁgure E2A in
online supplement) and goblet cells (MUC5AC, ﬁgure E2B in
online supplement). Cells also developed a network of localised
actin staining (see ﬁgure E2C in online supplement). Cultures
were wounded and repair followed over 24 h (see ﬁgure E1B in
online supplement). Immunostaining showed increased uPAR
Figure 4 Blocking the interaction between urokinase plasminogen activator (uPA) and urokinase plasminogen activator receptor (uPAR) alters
intracellular signalling. Cells were treated with (block, n¼4) or without (control, n¼8) blocking antibody and with (+) or without ( ) wounding for
5 min. Western blotting was performed for phosphorylated and total protein and b-actin (labelled P, T and B) for (A) Akt, (B) Erk1/2 and (C) p38MAPK;
representative blots shown. Densitometry was normalised to b-actin signal and gel intensity for total (DeF) and phosphorylated (GeI) proteins for
statistical analysis. The ratio of phosphorylated to total protein was also determined (JeL). *p<0.05, **p<0.01, ***p<0.001.
482 Thorax 2012;67:477e487. doi:10.1136/thoraxjnl-2011-200508
Asthmaexpression in cells at the wound edge 4 h after wounding (ﬁgure
6A). Expression of uPAR (p<0.001, ﬁgure 6B), uPA (p<0.001,
ﬁgure 6C) and PAI-1 (p<0.001, ﬁgure 6D) was increased at the
mRNA level during repair. suPAR, uPA and PAI-1 were increased
in supernatants from wounded cells (p<0.001, ﬁgure 6EeG).
MMP-2/MMP-9 were measured in supernatants by zymography
(not shown) and MMP-9 activity assay (ﬁgure 6H). MMP-2
activity was not always detected by zymography, suggesting
relatively low levels of expression; however, there was a trend
towards decreased expression in wounded cells (data not shown).
MMP-9 was increased in wounded cells (active p¼0.03, total
p¼0.004, ﬁgure 6H). Plasmin activity was measured in superna-
tants at 24 h after wounding. No signiﬁcant difference in activity
between wounded and unwounded cells was detected (ﬁgure 6I).
Figure 5 Increased urokinase plasminogen activator receptor (uPAR) expression leads to attenuated wound repair. Cells transfected with pc-uPAR
show elevated expression by (A) Western blotting with control (uPAR), (B) immunoﬂuorescence and (C) quantitative PCR 24 h after transfection
(n¼5). Increased soluble uPAR (suPAR) (D), decreased urokinase plasminogen activator (uPA) (E) and no change in plasminogen activator inhibitor 1
(PAI-1) (F) levels were observed in supernatants. Changes in matrix metalloproteinase (MMP)-9 and MMP-2 levels/activity were detected using (G)
zymography and (H) an ELISA-based assay. (I) Cells overexpressing uPAR showed attenuated wound repair. Control cells were treated with
supernatants from cells containing pc-DNA3 or pc-uPAR at wounding (J) or 24 h prior to wounding (K) and repair was measured (n $4, two donors).
*p<0.05, **p<0.01, ***p<0.001.
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AsthmaDISCUSSION
We hypothesised that a predisposition to altered uPAR expres-
sion may in part underlie our previously observed genetic asso-
ciation between PLAUR SNPs and asthma susceptibility, BHR
and increased decline in lung function in subjects with asthma.
1
Using a series of controls and individuals with asthma, we have
shown that uPAR expression is increased in the bronchus of
subjects with asthma, particularly in the epithelium, but there
was no correlation between disease severity and epithelial uPAR
staining, possibly due to limited power caused by the population
size. In addition, those with more severe disease are treated with
high-dose inhaled corticosteroids and/or oral corticosteroids
which may confound expression of uPAR. The relationship
between uPAR expression in the epithelium and airway
remodelling requires further investigation, but relating epithelial
histology to uPAR expression in a cross-sectional study would be
difﬁcult to interpret and is beyond the scope of this paper.
Previous studies have found uPAR levels to be increased in the
Figure 6 Induction of urokinase plasminogen activator receptor (uPAR) is a feature of primary bronchial epithelial cell (NHBEC) wound repair in an
aireliquid interface (ALI) differentiated model. Wound repair in differentiated NHBECs occurs over 24 h (representative of n¼2). (A) uPAR expression is
increased in cells at the wound edge 4 h after wounding (arrows). uPAR (B, E), urokinase plasminogen activator (uPA) (C, F) and plasminogen activator
inhibitor 1 (PAI-1) (D, G) mRNA and protein levels in supernatants were measured in wounded and unwounded cells over 24 h. Matrix
metalloproteinase 9 (MMP-9) (H) and plasmin (I) activity were measured at 24 h. *p<0.05, **p<0.01, ***p<0.001.
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Asthmasputum of patients with asthma
23 as well as in lung biopsies
from a single individual who died with asthma.
24 This is the ﬁrst
study to investigate the expression of uPAR protein ex vivo in
the airways of a number of control and asthmatic individuals.
These ﬁndings provide a basis for further investigation of the
role of uPAR in the epithelium. Using primary human NHBECs,
we have shown that alterations in the uPAR pathway are
a feature of epithelial repair. Blocking the uPAeuPAR interaction
attenuates repair while increased uPAR levels, as observed in
asthma, also attenuate repair.
We characterised the expression of uPAR pathway compo-
nents during primary bronchial epithelial cell wound repair in
both monolayer (summarised in ﬁgure 7A) and differentiated
culture models. The differentiated model consists of pseudos-
tratiﬁed cells at ALI,
17 18 showing signiﬁcant transepithelial
electrical resistance.
25 Cells develop localised actin (replacing the
diffuse expression seen in monolayer culture) and develop
expression of markers of ciliated and goblet cells, characteristic
of the bronchial epithelium in vivo. uPAR and PAI-1 mRNA
expression was increased during repair, and uPAR protein
expression was increased in cells at the wound edge. There was
also a signiﬁcant increase in suPAR in supernatants of wounded
cells in both models. In the ALI model only, uPA mRNA and uPA
and PAI-1 in supernatants were also increased. A previous study
comparing asthmatic and normal paediatric airway epithelial
cells also found increased PAI-1 mRNA and activity during
wound repair.
26 MMP-2/MMP-9 activation is a potential
downstream target of the proteolytic plasmin cascade.
27 28 Both
MMP-2 and MMP-9 have been shown to promote epithelial
migration and wound repair in various models.
22 29 30 In
monolayer culture, pro-MMP-2 was modestly decreased
after wounding. At ALI, MMP-9 activity was increased
while pro-MMP-2 was not always detected, suggesting that
patterns of MMP activation may differ depending on the
model and cell type used. We were not able to detect active
forms of MMP-2 and MMP-9 by zymography and MMP-2
activity was not speciﬁcally measured, limiting the conclusions
that can be drawn about MMP-2 activation in both our
wounding models. Differences between the two culture systems
may be driven by the different cellular composition present
(‘basal’ vs ‘differentiated’) and different culture conditions
(wounding vs differentiation medium (see Methods); 6-well
plate vs 12-well transwell insert). We consider the use of
both culture systems to be a strength of our approach but
acknowledge the limitations of direct comparison between the
systems.
uPAeuPAR binding may also trigger intracellular signalling
cascades, including PI3-kinase/Akt, p38MAPK and Erk1/2
31 32
(reviewed by Smith and Marshall
4). Previous data from our
group and others have shown that these signalling pathways are
also involved in epithelial wound repair.
18 33 34 We show
increased Erk1/2 and p38MAPK but not Akt phosphorylation
5 min after wounding in the monolayer system, suggesting that
either Akt is not activated on wound healing in our model or
that activation may occur at a different time point. We did not
perform this analysis in the ALI model, which is a limitation of
the current study.
Blocking the interaction of uPA and uPAR resulted in atten-
uation of wound repair and reduction in soluble pathway
components in cell supernatants (suPAR, uPA and PAI-1),
conﬁrming that the uPAR pathway is a component of repair.
Various studies have found that increased uPA induces uPA,
uPAR and PAI-1 expression in airway epithelial cells via mRNA
stabilisation.
35 We hypothesise that the binding of uPA by the
blocking antibody may have an opposite effect, leading to
downregulation of uPAR, uPA and PAI-1. It should be noted that
the blocking antibody will compete with the anti-uPA ELISA,
therefore the ELISA measurements of uPA may reﬂect only ‘free’
uPA in the supernatant. MMP-2/MMP-9 levels were not affected
by the addition of anti-uPA, suggesting that they are not directly
regulated by uPA levels. Treatment of the cells with plasmin or
aprotinin (a plasmin inhibitor) did not signiﬁcantly affect the
Figure 7 Targeting the urokinase plasminogen activator receptor (uPAR) pathway leads to attenuation of wound repair via different mechanisms.
Urokinase plasminogen activator (uPA) binding to uPAR activates both extracellular and intracellular signalling cascades. (A) Plasminogen activator
inhibitor 1 (PAI-1) binding to uPAR and its co-receptors interferes with signalling via multiple mechanisms. Damage to the epithelial layer leads to
increased soluble uPAR (suPAR) and phosphorylation of Erk1/2 and p38. (B) Blocking the interaction between uPA and uPAR at the time of damage
leads to decreased suPAR, uPA and PAI-1 in the supernatant, changes in activation of signalling pathways and attenuation of wound repair. (C)
Increased levels of uPAR lead to increased receptor shedding, changes in matrix metalloproteinase 9 (MMP-9) activity and attenuation of wound repair.
Soluble uPAR sequesters uPA and prevents it binding to cell surface uPAR.
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Asthmarate of repair (data not shown). In addition, in the differentiated
model, plasmin activity in supernatants was not affected by
wounding. These data suggest that attenuation of repair may
not be driven by the proteolytic plasmin cascade. Blocking the
interaction of uPA and uPAR resulted in changes in intracellular
signalling activation (ie, phosphorylation of Erk1/2 and
p38MAPK), suggesting that blocking acts via changes in the
balance between key intracellular signalling pathways involved
in the wound repair response (ﬁgure 7B). An isotype control
antibody showed some inhibition of wound healing; this effect
was not seen using a non-blocking isotype-matched anti-uPAR
domain II antibody. The anti-uPAR antibody was therefore used
as a control in intracellular signalling experiments, showing no
signiﬁcant effect on cell signalling.
We have shown that uPAR expression is increased in the
bronchial epithelium of subjects with asthma. We therefore
overexpressed uPAR in the NHBEC model. Transfected cells
showed high levels of surface uPAR and suPAR in the superna-
tant, potentially mimicking the increased levels of uPAR
observed in the epithelium and sputum
23 of patients with
asthma. Increased uPAR levels lead to a signiﬁcant attenuation
of repair which may reﬂect the previously observed reduced
capacity for epithelial repair of asthmatic versus control cells
in cell culture.
36 Supernatant uPA is signiﬁcantly decreased
24 h after uPAR overexpression; increased suPAR may
sequester uPA, preventing binding to surface uPAR. The soluble
receptor may also interact with cell surface molecules and
modulate signalling directly.
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activation was unchanged in uPAR over-expressing cells;
however, wound repair was attenuated. Overexpression of uPAR
also increased baseline MMP-9 activity, suggesting a change in
cell phenotype.
Cells pretreated with pc-uPAR-conditioned supernatants
showed a reduction in wound healing which was not present
when treated at the time of wounding. This change was modest,
suggesting that soluble factors may not play a major role in
attenuating repair in our model. However, a study in a breast
cancer cell line showed that suPAR decreased matrigel invasion
only when cells were preincubated for 6e18 h. Similarly,
a transwell migration assay with 15 min preincubation showed
no effect of suPAR.
7 These data support the proposal that suPAR
treatment or overexpression may induce an altered phenotype
and that changes take time to occur. We hypothesise that
overexpression of uPAR results in increased receptor shedding,
generating suPAR which sequesters uPA. Signalling via surface
uPAR and suPAR modiﬁes the cell phenotype, including
increased MMP-9 activity, via as yet unexplored mechanisms to
reduce the ability of the cells to respond to repair signals (ﬁgure
7C). These changes may be signiﬁcant for epithelial function in
patients with asthma.
Overall, this study shows that uPAR is increased in the bron-
chial epithelium in asthma and that the uPAR pathway is
upregulated during wound repair in primary NHBECs in vitro,
both in monolayer culture and a differentiated model. Blocking
the interaction between uPA and uPAR attenuates repair via
modulation of intracellular kinase cascades, while overexpression
of uPAR results in attenuation of wound repair via increased
receptor shedding and potential alterations in cell phenotype in
vitro. Our data suggest that the interaction between uPA and
membrane uPAR is an important stage in the epithelial repair
process. A late increase in soluble uPAR may be a feedback loop
associated with resolution of repair, with soluble uPAR poten-
tially acting to sequester uPA and prevent its binding to surface
uPAR, as suggested in the overexpression model.
In asthma there is increased epithelial expression of uPAR and,
importantly, soluble cleaved uPAR (as measured in sputum).
23
We have previously shown a genetic association of PLAUR SNPs
with increased BHR, increased rate of decline in lung function
and increased plasma/serum levels of uPAR in patients with
asthma.
1 The current data support the hypothesis that patients
with asthma may be genetically predisposed to increased uPAR
expression, so this feedback loop may be sustained in asthma,
ultimately leading to disruption of bronchial epithelial repair
homeostasis which may be a factor in the development of
airway remodelling and increased decline in lung function. The
uPAeuPAR axis may therefore be a novel therapeutic opportu-
nity to target these mechanisms, which are not adequately
addressed by existing drugs in asthma.
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Journal club
Lebrikizumab may beneﬁt a subset of patients with
asthma
Interleukin 13 (IL-13), a cytokine of type 2 helper Tcells, may contribute to the heterogeneity
of asthma in terms of clinical course and response to treatment. IL-13 leads to the production
of periostin, a protein that may cause airway remodelling.
In this randomised, double-blind, placebo-controlled study, lebrikizumab, a monoclonal
antibody that binds to IL-13 thereby inhibiting its function, was used to investigate the effect
on patients with uncontrolled asthma undergoing treatment with inhaled steroids.
Lebrikizumab showed superior primary outcome to placebo, with an increase in pre-
bronchodilator forced expiratory volume in one second (FEV1) by 5.5% at week 12. Patients
with higher periostin levels had a relative increase in FEV1 of 8.2% compared with those
receiving placebo, whereas the low periostin group had a relative increase in FEV1 of 1.6% over
the placebo group. There was no signiﬁcant improvement in secondary outcomes including
rates of asthma exacerbation, asthma symptom scores or use of rescue medications. The
secondary outcome results may have been limited by the study length of 24 weeks. There was
deﬁnitely a percentage decline in exacerbation rates in the lebrikizumab group in patients
with high Th2, periostin and fraction of exhaled nitric oxide values but these were not
statistically signiﬁcant.
This study shows the potential use of biomarkers to target speciﬁc patients with asthma
who would beneﬁt from treatment. Further multicentre studies using larger numbers of
patients over a greater time period should be conducted to conﬁrm and expand on the results
of the current study.
< Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088e98.
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